7.51 USD
+0.51 (+7.29%)
7.55 USD
+0.04 (+0.53%)
Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of KZIA have multiple concerns. KZIA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year KZIA has reported negative net income.
- In the past year KZIA has reported a negative cash flow from operations.
- In the past 5 years KZIA always reported negative net income.
- In the past 5 years KZIA always reported negative operating cash flow.
1.2 Ratios
- KZIA's Return On Assets of -158.60% is on the low side compared to the rest of the industry. KZIA is outperformed by 85.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -158.6% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for KZIA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for KZIA has been increased compared to 1 year ago.
- The number of shares outstanding for KZIA has been increased compared to 5 years ago.
- KZIA has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -12.30, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of KZIA (-12.30) is worse than 76.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
- The Current ratio of KZIA (0.21) is worse than 93.14% of its industry peers.
- A Quick Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
- KZIA's Quick ratio of 0.21 is on the low side compared to the rest of the industry. KZIA is outperformed by 92.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.21 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
- KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.01%, which is quite impressive.
- The Revenue for KZIA has decreased by -95.09% in the past year. This is quite bad
- KZIA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.58% yearly.
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
3.2 Future
- KZIA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.16% yearly.
- Based on estimates for the next years, KZIA will show a very strong growth in Revenue. The Revenue will grow by 377.88% on average per year.
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.16%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y377.89%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
- Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- KZIA's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
- KZIA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What is the fundamental rating for KZIA stock?
ChartMill assigns a fundamental rating of 1 / 10 to KZIA.
What is the valuation status for KZIA stock?
ChartMill assigns a valuation rating of 1 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.
Can you provide the profitability details for KAZIA THERAPEUTICS-SPON ADR?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 0 / 10.
How financially healthy is KAZIA THERAPEUTICS-SPON ADR?
The financial health rating of KAZIA THERAPEUTICS-SPON ADR (KZIA) is 0 / 10.
What is the earnings growth outlook for KAZIA THERAPEUTICS-SPON ADR?
The Earnings per Share (EPS) of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to grow by 79.58% in the next year.